Thiobutyrolactone

Thiobutyrolactone

SCHEMBL1021969

O=C1CCCS1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiobutyrolactone SCHEMBL13480 1.00
SCHEMBL1026885 0.90
SCHEMBL1024355 0.90
Hydrochloric Acid SCHEMBL17701165 0.88 ALDH1A1 (0.37)
SCHEMBL19484930 0.88 ALDH1A1 (0.40)
SCHEMBL23572609 0.88 ALDH1A1 (0.40)
SCHEMBL1024258 0.88
SCHEMBL19485084 0.88 ALDH1A1 (0.40)
SCHEMBL1023901 0.88
SCHEMBL1024256 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2277510-B1 Controlled release preparation TAKEDA PHARMACEUTICALS CO (JP) 2018-12-26 EP disclosed
EP-2275088-B2 Method for producing granules TAKEDA PHARMACEUTICALS CO (JP) 2018-09-26 EP disclosed
EP-1602362-B1 DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE TAKEDA PHARMACEUTICAL (JP) 2016-09-28 EP disclosed
US-20160128945-A1 CONTROLLED RELEASE PREPARATION TAKEDA PHARMACEUTICAL (JP) 2016-05-12 US disclosed
EP-2275088-B1 Method for producing granules TAKEDA PHARMACEUTICAL (JP) 2015-09-02 EP disclosed
US-9011926-B2 Method for producing granules TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-21 US disclosed
US-8980322-B2 Controlled release composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-03-17 US disclosed
US-20150072015-A1 METHOD FOR PRODUCING GRANULES TAKEDA PHARMACEUTICAL (JP) 2015-03-12 US disclosed
US-8871273-B2 Method for producing granules TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-10-28 US disclosed
US-8784885-B2 Controlled release preparation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-07-22 US disclosed
EP-1607088-A1 CONTROLLED RELEASE COMPOSITION Takeda Pharmaceutical Company Limited (JP) 2005-12-21 EP disclosed
EP-1602362-A1 DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE Takeda Pharmaceutical Company Limited (JP) 2005-12-07 EP disclosed
US-20050222210-A1 Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-06 US disclosed
EP-1553929-A2 CONTROLLED RELEASE PREPARATION Takeda Pharmaceutical Company Limited (JP) 2005-07-20 EP disclosed
EP-1513527-A1 PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
EP-1514870-A1 PRODRUG AND PROCESS FOR PRODUCING THE SAME Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
US-20040259912-A1 Benzine derivatives, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-12-23 US disclosed
EP-1437344-A1 BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-07-14 EP disclosed
WO-2004035020-A2 CONTROLLED RELEASE PREPARATION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 WO disclosed
WO-2003105845-A1 PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-12-24 WO disclosed